Finally, we demonstrate the synergistic potential of concurrent pharmacological targeting on UCK2 and EGFR in HCC treatment in both xenograft and patient-derived xenograft (PDX) models. This evidence concerns the gene UCK2 and hepatocellular carcinoma.